Innovating Works
NFRP-2019-2020-14
NFRP-2019-2020-14: Improving low-dose radiation risk appraisal in medicine
Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, medical applications are the main contributor to the exposure of the European population to ionising radiation. The use of appropriate radioisotopes in nuclear medicine in diagnostic and therapy (theranostics) is progressing. The reinforced risk appraisal of medical exposure will reinforce consideration of benefits. It includes the selection of appropriate radioactive cytostatic compounds and the establishment of adequate controls of their discharges in water streams by selecting short-lived radioisotopes that take into account the protection of workers, carers and comforters, the public and the environment. These progresses will be faster if more certainty about overall detriment is available. Moreover, the medical sector is the best place to keep record of the overall health condition of patients. Thus, using data of patients in the medical sector together with radiation exposure records will improve knowledge. Previous funding efforts have launched collaboration between radiological protection specialists and medical doctors. It deserves further collaboration as results can be used for other exposure situations.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 25-09-2019.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, medical applications are the main contributor to the exposure of the European population to ionising radiation. The use of appropriate radioisotopes in nuclear medicine in diagnostic and therapy (theranostics) is progressing. The reinforced risk appraisal of medical exposure will reinforce consideration of benefits. It includes the selection of appropriate radioactive cytostatic compounds and the establishment of adequate controls of their discharges in water streams by selecting short-lived radioisotopes that take into account the protection of workers, carers and comforters, the public and the environment. These progresses will be faster if more certainty about overall detriment is available. Moreover, the medical sector is the best place to keep record of the overall health condition of patients. Thus, using data of patients in the medical sector together with radiation exposure records will improve knowledge. Previous funding efforts have launched collaboration between radiological protection specialists and medical doctors. It deserves furth... ver más

Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, medical applications are the main contributor to the exposure of the European population to ionising radiation. The use of appropriate radioisotopes in nuclear medicine in diagnostic and therapy (theranostics) is progressing. The reinforced risk appraisal of medical exposure will reinforce consideration of benefits. It includes the selection of appropriate radioactive cytostatic compounds and the establishment of adequate controls of their discharges in water streams by selecting short-lived radioisotopes that take into account the protection of workers, carers and comforters, the public and the environment. These progresses will be faster if more certainty about overall detriment is available. Moreover, the medical sector is the best place to keep record of the overall health condition of patients. Thus, using data of patients in the medical sector together with radiation exposure records will improve knowledge. Previous funding efforts have launched collaboration between radiological protection specialists and medical doctors. It deserves further collaboration as results can be used for other exposure situations.


Scope:

This action should add clarity on detriment from new medical applications of ionising radiation in view of their fast deployment. This should include harmonised patient data collection from different disciplines and treatment approaches in order to enable deduction of the mechanisms leading to health detriment and to enable improved treatment. This should apply due consideration to double causation and peculiar conditions to medical procedures. This action should take into account the gap analysis performed by MELODI, EURADOS and EURAMED, and address the key issue of individual sensitivity and susceptibility to radiation. The proposal should include methods for radiation detriment appraisal with demonstrable shift from the current metrics. It should take due account of previous research that is cross-cutting with health and radiological protection. This data should include data collected from imaging procedures benefiting to the most sensitive, extensive and long lasting followed-up category of patients. It should also include data on most exposed medical staff as well as patients of nuclear medicine, including theranostics. It should also provide recommendations on radiological protection for the development of new applications of radiation in medical care, per category and per procedure. It should involve radiology and therapy equipment manufacturers or their associations, European associations of researchers in this field, organisations having a regulatory mandate for radiation protection research from Member States or EU bodies and universities and hospitals. It should also involve radioisotope developers and suppliers. Proposals in this topic should take into consideration risk communication and the ethics of medical applications.

At least 5% of the total action budget must be dedicated to Education and Training activities for PhD students, postdoctoral researchers and trainees supported through the action (see Conditions for the Call- Eligibility and admissibility conditions).

The Commission considers that proposals requesting a contribution from the Euratom Programme up to EUR 6.0 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.


Expected Impact: New applications of radiation in medical care will be able to use fast-track approval procedures thanks to the better appraisal of their possible health detriment. This action will improve risk assessment capabilities of the two main sources of radiation exposure of the European population through improved knowledge on internal exposure. In the long term, it will help controlling the discharge of cytostatic compounds in the environment.


ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, medical applications are the main contributor to the exposure of the European population to ionising radiation. The use of appropriate radioisotopes in nuclear medicine in diagnostic and therapy (theranostics) is progressing. The reinforced risk appraisal of medical exposure will reinforce consideration of benefits. It includes the selection of appropriate radioactive cytostatic compounds and the establishment of adequate controls of their discharges in water streams by selecting short-lived radioisotopes that take into account the protection of workers, carers and comforters, the public and the environment. These progresses will be faster if more certainty about overall detriment is available. Moreover, the medical sector is the best place to keep record of the overall health condition of patients. Thus, using data of patients in the medical sector together with radiation exposure records will improve knowledge. Previous funding efforts have launched collaboration between radiological protection specialists and medical doctors. It deserves further collaboration as results can be used for other exposure situations. Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, medical applications are the main contributor to the exposure of the European population to ionising radiation. The use of appropriate radioisotopes in nuclear medicine in diagnostic and therapy (theranostics) is progressing. The reinforced risk appraisal of medical exposure will reinforce consideration of benefits. It includes the selection of appropriate radioactive cytostatic compounds and the establishment of adequate controls of their discharges in water streams by selecting short-lived radioisotopes that take into account the protection of workers, carers and comforters, the public and the environment. These progresses will be faster if more certainty about overall detriment is available. Moreover, the medical sector is the best place to keep record of the overall health condition of patients. Thus, using data of patients in the medical sector together with radiation exposure records will improve knowledge. Previous funding efforts have launched collaboration between radiological protection specialists and medical doctors. It deserves further collaboration as results can be used for other exposure situations.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
1. Eligible countries: described in part A of the General Annexes of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
 
2. Eligibility and admissibility conditions: described in part B and part C of the General Annexes of the Work Programme. 
 
In order to stimulate training and mobility of researchers (as mandated by Regulation (Euratom) No 2018/1563) in these topics, at least 5% of the total action budget must be dedicated to Education and Training activities for PhD students, postdoctoral researchers and trainees supported through the action. Proposals must indicate how this condition is met by including under "resources to be committed" in Section 3.4c of the Part B of the proposal, the total allocation of budget to the related work-package(s) or part(s) of work-package.
Personnel costs related to the work performed on the action by PhD students, postdoctoral researchers and trainees is considered to be part of education and training activities.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
 
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in part G of the General Annexes of the...
1. Eligible countries: described in part A of the General Annexes of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
 
2. Eligibility and admissibility conditions: described in part B and part C of the General Annexes of the Work Programme. 
 
In order to stimulate training and mobility of researchers (as mandated by Regulation (Euratom) No 2018/1563) in these topics, at least 5% of the total action budget must be dedicated to Education and Training activities for PhD students, postdoctoral researchers and trainees supported through the action. Proposals must indicate how this condition is met by including under "resources to be committed" in Section 3.4c of the Part B of the proposal, the total allocation of budget to the related work-package(s) or part(s) of work-package.
Personnel costs related to the work performed on the action by PhD students, postdoctoral researchers and trainees is considered to be part of education and training activities.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
 
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in part G of the General Annexes of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
 
6. Additional provisions:
Horizon 2020 budget flexibility - part H of the General Annexes of the Work Programme
Classified information - part I of the General Annexes of the Work Programme 
Technology readiness levels (TRL) - part F of the General Annexes of the Work Programme – where a topic description refers to TRL, these definitions apply
 
For grants awarded under this topic beneficiaries may provide support to third parties as described in part J of the General Annexes of the Work Programme. The support to third parties can only be provided in the form of grants. The respective options of Article 15.1 and Article 15.3 of the Model Grant Agreement will be applied.
Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in part K of the General Annexes of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
 
8. Additional documents:
Euratom Work Programme 2019-20
Legal basis: Euratom Research and Training Programme 2019-2020 
Legal basis: Horizon 2020 Rules for Participation
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
NFRP-2019-2020 Improving low-dose radiation risk appraisal in medicine Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, me...
Sin info.
NFRP-2019-2020-13 Research roadmap for medical applications of ionising radiation
en consorcio: Specific Challenge:Nuclear and ionising radiation technologies have a central place in modern medicine, saving lives and improving the quali...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NFRP-2019-2020-14 Improving low-dose radiation risk appraisal in medicine
en consorcio: Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, me...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NFRP-2019-2020-10 Developing pre-disposal activities identified in the scope of the European Joint Programme in Radioactive Waste Management
en consorcio: Specific Challenge:In Europe, the challenges in the field of radioactive waste management (RWM) include: To improve, innovate and develop s...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NFRP-2019-2020-03 Safety margins determination for design basis-exceeding external hazards
en consorcio: Specific Challenge:EU nuclear plants need to demonstrate compliance with evolving and stringent safety requirements. These research actions...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NFRP-2019-2020-05 Support for safety research of Small Modular Reactors
en consorcio: Specific Challenge: Small Modular Reactors (SMRs) are considered as a reasonable option to cover future energy needs and applications like e...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de